USOO8883481 B2
(12) United States Patent (10) Patent No.: US 8,883,481 B2 Dormitzer et al. (45) Date of Patent: Nov. 11, 2014
(54) REVERSE GENETICS METHODS FOR VIRUS (56) References Cited RESCUE U.S. PATENT DOCUMENTS (75) Inventors: Philipso Dormitzer, Weston, MA (US); 6,455,298 B1* 9/2002 Groner et al...... 435/235.1 Björn Keiner, Marburg (DE); Pirada 2008/O124803 A1 5/2008 Billeter et al. Suphaphiphat, Brookline, MA (US); Michael Franti, Quebec (CA); Peter FOREIGN PATENT DOCUMENTS Mason, Sommerville, MA (US); WO WO-2003/091401 4/2003 ennifer Uhlendorff, Neuss (DE): WO WO-2005/062820 7/2005 Mikhail Matrosovich, Marburg (DE) WO WO-2007/047459 7/2005 WO WO-2010/046335 4/2010 (73) Assignee: Novartis AG, Basel (CH) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer the term of this Wang et al. Cloning of the canine RNA polymerase I promoter and patent is extended or adjusted under 35 establishment of reverse genetics for influenza A and B in MDCK U.S.C. 154(b) by 17 days. cells. Virology Journal 2007, vol. 4, p. 102-113.* Nicolson et al. Generation of influenza vaccine viruses on Vero cells (21) Appl. No.: 13/503,353 by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, vol. 23, pp. 2943-2952.* Koudstaal et al. (Apr. 28, 2009). "Suitability of PerC6 cells to gen (22) PCT Filed: Oct. 20, 2010 erate epidemic and pandemic influenza vaccine strains by reverse genetics.” Vaccine 27(19):2588-93. (86). PCT No.: PCT/B2010/054752 Neumann (2003). “Reverse genetics for the control of avian influ enza.” Avian Dis. 47(3 Suppl):882-7. S371 (c)(1), Suphaphiphatet al. (Apr. 2010). “Human RNA Polymerase I-Driven (2), (4) Date: Oct. 11, 2012 Reverse Genetics for Influenza A Virus in Canine Cells.' J. Virol. vol. 84 No. 73721-3725. (87) PCT Pub. No.: WO2011/048560 Whiteleyetal. (Jul. 2007). "Generation of candidate human influenza vaccine strains in cell culture—rehearsing the European response to PCT Pub. Date: Apr. 28, 2011 an H7N1 pandemic threat.” Influenza. Other RespiViruses. 1(4): 157 66. (65) Prior Publication Data Zhang et al. (Sep. 2009). "A one-plasmid system to generate influ enza virus in cultured chicken cells for potential use in influenza US 2013/0034582 A1 Feb. 7, 2013 vaccine.” JVirol. 83(18):9296-303. International Search Report mailed on Feb. 21, 2012, for Interna tional Patent Application No. PCT/IB2010/054752, filed on Oct. 20, Related U.S. ApplicationO O Data International2010. Preliminary Report on Patentability mailed on Jul. 27. (60) Provisional application No. 61/279.487, filed on Oct. 2012, for International Patent Application No. PCT/IB2010/054752, 20, 2009. filed on Oct. 20, 2010. s Xuan, Bai (2008). “The Construction of Rotavirus Group a Reassort ment strain by Reverse Genetics.” China Master's Thesis Full Text (51) Int. Cl. Database, No. 12. Available online at
FGURE
O ?ae?***…×××××××××××××××, %.
U.S. Patent Nov. 11, 2014 Sheet 2 of 4 US 8,883,481 B2
FGURE 2
------|90+=00|| –––.Z0+='00"| U.S. Patent Nov. 11, 2014 Sheet 3 of 4 US 8,883,481 B2
FIGURE 3
U.S. Patent Nov. 11, 2014 Sheet 4 of 4 US 8,883,481 B2
FGURE 4
------'------.l ...... YY YYYYYYYYYYYYYYYYYY YYYYYY 33YYYX Y33. US 8,883,481 B2 1. 2 REVERSE GENETCS METHODS FOR VIRUS mixture of cells; (iii) culturing the mixture of cells in order to RESCUE produce virus; (iv) purifying the virus obtained in step (iii) and optionally (V) formulating the virus into a vaccine. CROSS REFERENCE TO RELATED Reverse Genetics APPLICATIONS Reverse genetics can be used for the production of a wide variety of RNA viruses, including positive-strand RNA This application is a U.S. National Phase patent application viruses 1.2, negative-strand RNA viruses 3,4 and double of PCT/IB2010/054752, filed Oct. 20, 2010, which claims stranded RNA viruses 5. Thus, the present invention pro priority to U.S. provisional patent application Ser. No. vides a method for producing a recombinant virus wherein 10 the virus is obtained using the reverse genetics method of the 61/279,487 filed Oct. 20, 2009, all of which are hereby incor present invention. porated by reference in the present disclosure in their entirety. Known reverse genetics systems involve expressing DNA SUBMISSION OF SEQUENCE LISTING AS molecules which encode desired viral. RNA (VRNA) mol ASCII TEXT FILE ecules from pol I promoters, bacterial RNA polymerase pro 15 moters, bacteriophage polymerase promoters, etc. Further The content of the following submission on ASCII text file more, where a virus requires certain proteins to form an is incorporated herein by reference in its entirety: a computer infectious virus, the systems also provide these proteins e.g. readable form (CRF) of the Sequence Listing (file name: the system further comprises DNA molecules that encode 223.002124600SeqList.txt, date recorded: Apr. 13, 2012, size: viral proteins such that expression of both types of DNA leads 18 KB). to assembly of a complete infectious virus. Where reverse genetics is used for the expression of vRNA, TECHNICAL FIELD it will be evident to the person skilled in the art that precise spacing of the sequence elements with reference to each other This invention is in the field of reverse genetics. Further is pivotal for the polymerase to initiate replication. It is there more, it relates to manufacturing vaccines for protecting 25 fore important that the DNA molecule encoding the viral against various viruses. RNA is positioned correctly between the pol I promoter and the termination sequence, but this positioning is well within BACKGROUND ART the capabilities of those who work with reverse genetics sys temS. Reverse genetics permits the recombinant expression and 30 Generally, reverse genetics is suitable for expression of any manipulation of RNA viruses in cell culture. It is a powerful viruses which are known to require production of genomic tool in Virology and vaccine manufacture because it allows RNA during their life-cycle. Such viruses include, but are not rapid production of recombinant viruses (including reassor limited to, positive-strand and negative-strand RNA viruses, tants) and/or their mutation. The method involves transfect such as those described below. Preferably, the virus is an ing host cells with one or more expression constructs that 35 orthomyxovirus, e.g., an influenza virus. The methods of the encode the viral genome and isolating the virus from the cells. invention are further suitable for non-segmented as well as One drawback with virus rescue by reverse genetics is that segmented viruses. the process is inefficient and frequently results in an unsatis Where the virus is a positive-strand RNA virus it is often factory virus yield. Thus there remains a need in the art to Sufficient to transfect a cell with an expression construct provide alternative and more efficient reverse genetics meth 40 comprising the viral genome. For example, the transfection of ods. plasmids containing the poliovirus genome resulted in the recovery of infectious poliovirus 1.2. Reverse genetics for SUMMARY OF PREFERREDEMBODIMENTS negative-strand RNA viruses has presented more challenges as the antisense viral RNA is usually non-infective and The inventors have now surprisingly discovered that the 45 requires an RNA polymerase to complete the life cycle. Thus, poor efficiency of reverse genetics methods can be improved the viral polymerase must be supplied, either as protein or as significantly by transfecting cells with the reverse genetics a gene for in situ protein expression. construct(s) and Subsequently adding more cells to the trans Where the virus requires a protein for infectivity, it is fected cells. The inventors surmise that the observed increase generally preferred to use bi-directional expression con in efficiency is due to the fact that transfection is harmful to 50 structs as this reduces the total number of expression con the cells. Thus, any viruses which are rescued need to expand structs required by the host cell. Thus, the method of the in sick cells or wait until the virus is transferred to healthy invention may utilise at least one bi-directional expression cells. This results in a loss of viable virus. The addition of construct wherein a gene or cDNA is located between an cells to the transfected host cells allows the rescued virus to upstreampol II promoter and a downstream non-endogenous multiply on a healthy cell substrate which increases the virus 55 pol I promoter. Transcription of the gene or cDNA from the yield significantly. pol II promoter produces capped positive-sense viral mRNA In one embodiment, the invention provides a method for which can be translated into a protein, while transcription preparing a virus comprising the steps of (i) transfecting a from the non-endogenous pol I promoter produces negative culture of host cells with at least one expression construct sense VRNA. The bi-directional expression construct may be encoding a viral RNA molecule; (ii) adding cells to the trans 60 a bi-directional expression vector. fected host cells of (i) to provide a mixture of cells; and (iii) In order to produce a recombinant virus, a cell must express culturing the mixture of cells in order to produce virus. all segments of the viral genome which are necessary to In a further embodiment, the invention provides a method assemble a virion. DNA cloned into the expression constructs of preparing a virus for vaccine manufacture, comprising the of the present invention preferably provides all of the viral steps of (i) transfecting a culture of host cells with at least one 65 RNA and proteins, but it is also possible to use a helper virus expression construct encoding a viral RNA molecule; (ii) to provide some of the RNA and proteins, although systems adding cells to the transfected host cells of (i) to provide a which do not use a helper virus are preferred. Where the virus US 8,883,481 B2 3 4 is a non-segmented virus this can usually be achieved by carnivora, marsupialia, cetacean, etc. Humans and chimpan utilising a single expression construct in the method of the Zees are in the same taxonomic order (primates), but humans invention, even though it is also within the scope of the and dogs are in different orders (primates vs. carnivora). invention to express the viral genome of non-segmented In the methods of the invention, a host cell may be trans viruses using more than one expression construct. Where the fected with at least two, at least three, at least four, at least five, virus is a segmented virus, the viral genome is usually at least six, at least seven, at least eight, at least nine, at least expressed using more than one expression construct in the ten, at least eleven or at least twelve expression constructs. method of the invention. It is also envisioned, however, to An expression construct may be a vector, such as a plasmid combine one or more segments or even all segments of the or other episomal construct. Such vectors will typically com viral genome on a single expression construct. 10 prise at least one bacterial and/or eukaryotic origin of repli Methods of the invention are particularly suitable for the cation. Furthermore, the vector may comprise a selectable production of reassortant virus strains. The technique can use marker which allows for selection in prokaryotic and/or in vitro manipulation of plasmids to generate combinations of eukaryotic cells. Examples of Such selectable markers are viral segments, to facilitate manipulation of coding or non genes conferring resistance to antibiotics, such as amplicillin coding sequences in the viral segments, to introduce muta 15 or kanamycin. The vector may further comprise one or more tions, etc. The use of the expression system for the production multiple cloning sites to facilitate cloning of a DNA of reassortant virus strains is preferred as this can signifi Sequence. cantly decrease the time needed to obtain a reassortant seed As an alternative, an expression construct may be a linear virus which is particularly beneficial in situations where a expression construct. Such linear expression constructs will rapid production of vaccine is needed to counteract an epi typically not contain any amplification and/or selection demic. Thus, it is preferred that the method of this aspect of sequences. However, linear constructs comprising Such the invention uses one or more expression constructs that amplification and/or selection sequences are also within the express viral genes from or derived from at least two different Scope of the present invention. An example of a method using wild type strains. Such linear expression constructs for the expression of influ An expression construct which leads to expression of an 25 enza virus is described in reference 6. accessory protein in the host cell can also be used. For Expression constructs of the invention can be generated instance, it can be advantageous to express a non-viral serine using methods known in the art. Such methods were protease (e.g. trypsin) as part of a reverse genetics system. described, for example, in reference 7. Where the expression Expression Constructs construct is a linear expression construct, it is possible to The expression constructs encoding the viral RNA mol 30 linearise it before introduction into the host cell utilising a ecules for use in the invention can be any expression construct single restriction enzyme site. Alternatively, it is possible to commonly used in the art to rescue viruses. excise the expression construct from a vector using at least The expression constructs used may be uni-directional or two restriction enzyme sites. Furthermore, it is also possible bi-directional expression constructs. Where a host cell to obtain a linear expression construct by amplifying it using expresses more than one transgene (whether on the same or 35 a nucleic acid amplification technique (e.g. by PCR). different expression constructs) it is possible to use uni-di Where the expression host is a canine cell, such as a MDCK rectional and/or bi-directional expression. cell line, protein-coding regions may be optimised for canine Bi-directional expression constructs contain at least two expression e.g. using a promoter from a wild-type canine promoters which drive expression in different directions (i.e. gene or from a canine virus, and/or having codon usage more both 5' to 3' and 3' to 5") from the same construct. The two 40 suitable for canine cells than for human cells. For instance, promoters can be operably linked to different strands of the whereas human genes slightly favour UUC as the codon for same double stranded DNA. Preferably, one of the promoters Phe (54%), in canine cells the preference is stronger (59%). is a pol I promoter and at least one of the other promoters is a Similarly, whereas there is no majority preference for Ile pol II promoter. This is useful as the pol I promoter can be codons inhumancells, 53% of canine codons use AUC for Ile. used to express uncapped cRNAs while the pol II promoter 45 Canine viruses, such as canine parvovirus (a ssDNA virus) can be used to transcribe mRNAs which can subsequently be can also provide guidance for codon optimisation e.g. 95% of translated into proteins, thus allowing simultaneous expres Phe codons in canine parvovirus sequences are UUU (vs. sion of RNA and protein from the same construct. 41% in the canine genome), 68% of Ile codons are AUU (vs. The expression construct (whether uni-directional or bi 32%), 46% of Val codons are GUU (vs. 14%), 72% of Pro directional) will typically include an RNA transcription ter 50 codons are CCA (vs. 25%), 87% of Tyrcodons are UAU (vs. mination sequence. The termination sequence may be an 40%), 87% of His codons are CAU (vs. 39%), 92% of Gln endogenous termination sequence or a termination sequence codons are CAA (vs. 25%), 81% of Glucodons are GAA (vs. which is not endogenous to the host cell. Suitable termination 40%), 94% of Cys codons are UGU(vs. 42%), only 1% of Ser sequences will be evident to those of skill in the art and codons are UCU (vs. 24%), CCC is never used for Phe and include, but are not limited to, RNA polymerase I transcrip 55 UAG is never used as a stop codon. Thus protein-coding tion termination sequence, RNA polymerase II transcription genes can be made more like genes which nature has already tea initiation sequence, and ribozymes. Furthermore, the optimised for expression in canine cells, thereby facilitating expression constructs may contain one or more polyadenyla expression. tion signals for mRNAS, particularly at the end of a gene Transfection whose expression is controlled by a pol II promoter. 60 “Transfection” refers to the introduction of DNA into a The pol I and pol II promoters used in the expression cell. The expression constructs can be introduced into host constructs can be derived from an organism in the same cells using any technique known to those of skill in the art. For taxonomic order as the host cell in which the expression example, they can be introduced into host cells by employing construct is expressed. Alternatively, the promoters can be electroporation, DEAE-dextran, calcium phosphate precipi derived from an organism in a different taxonomic order than 65 tation, liposomes, microinjection, or microparticle-bombard the host cell. The term “order” refers to conventional taxo ment. Reverse genetics is commonly practised using the lipo nomic ranking, and examples of orders are primates, rodentia, Some method, for example using the transfection reagent US 8,883,481 B2 5 6 LipofectamineTM. The methods of the invention are not for use in the present invention. Likewise, transfected cells restricted to transfection with liposomes, however, but are can be used in the methods of the present invention provided expected to work equally well with other transfection meth that transfection does not occur shortly (i.e. within 48 hours) ods. before the cells are used in the methods of the present inven The cells can be added to the transfected host cells any time tion. up to 72 hours after transfection. For example, the cells may Where the rescued virus requires the presence of a protease be added immediately after transfection, 5 minutes, 10 min for infectivity it will be advantageous to add the protease utes, 20 minutes, 30 minutes, 1 hour, 2hours, 3 hours, 6 hours, together with the cells after transfection. For example, the 12 hours, 24 hours, 36 hours, 48 hours, 60 hours or 72 hours influenza virus requires the activity of a serine protease, like after transfection. Generally, the maximum time by which 10 trypsin, for infection. Thus, when the method of the invention cells are added after transfection will match the maximum is used to rescue influenza viruses, the serine protease can be time for which the transfected cells can survive. added at the same time as the cells after transfection. Alter The period “after transfection' starts once the DNA has natively, the protease can be added before or after the cells are been introduced into host cells within the culture. The time added to the transfected cells. point at which the DNA is introduced will vary with various 15 Cells factors, for example the cell line used, the method of trans The present invention can be practised with any eukaryotic fection or the temperature at which transfection is performed. cell that can produce the virus of interest. The invention will The time can be easily determined by the skilled person using typically use a cell line although, for example, primary cells standard methods. For example, several experiments can be may be used as an alternative. The cell will typically be conducted in parallel wherein the cells are transfected with mammalian. Suitable mammalian cells include, but are not reverse genetics constructs under identical conditions except limited to, hamster, cattle, primate (including humans and that transfection is stopped at different time points. If the monkeys) and dog cells. Various cell types may be used. Such DNA has been introduced into the host cell then at least one as kidney cells, fibroblasts, retinal cells, lung cells, etc. virus should have formed. Thus, the skilled person can assay Examples of suitable hamster cells are the cell lines having for the presence of a virus, for example by determining the 25 the names BHK21 or HKCC. Suitable monkey cells are e.g. number of plaque forming units using standard assays. The African green monkey cells, such as kidney cells as in the first time point after which at least one plaque forming unit Vero cell line 8-10. Suitable dog cells are e.g. kidney cells, (PFU) is detectable is the time point when the DNA has been as in the CLDK and MDCK cell lines. introduced into the host cell. Further suitable cells include, but are not limited to: CHO: Alternatively, the period after which cells are added to the 30 293T; BHK: MRC 5: PERC611: FRhL2: WI-38; etc. Suit transfected cells can be determined from the start of the able cells are widely available e.g. from the American Type transfection. The start of transfection is the time point at Cell Culture (ATCC) collection 12, from the Coriell. Cell which the expression construct(s) encoding the viral mol Repositories 13, or from the European Collection of Cell ecule(s) are contacted with the culture of host cells. Thus, the Cultures (ECACC). For example, the ATCC supplies various cells can be added to the transfected cells any time up to 96 35 different Vero cells under catalogue numbers CCL 81, CCL hours after the start of transfection, for example, 12 hours, 24 81.2, CRL 1586 and CRL-1587, and it supplies MDCK cells hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours or 96 under catalogue number CCL 34. PER.C6 is available from hours. While the time point “after transfection' and the time the ECACC under deposit number 96022940. MDCK, Vero point “from the start of transfection” are measured relative to and PER.C6 cells are commonly used for the production of different starting points, the absolute time when the cells are 40 viruses and therefore each of these cells lines is particularly added to the infected cells can be the same. For example, if it suitable for use with the methods of the present invention. takes 1 hour for the DNA to be introduced into the host cells Preferred cells (particularly for growing influenza viruses) in a culture and the cells are added 30 minutes after the DNA for use in the invention are MDCK cells 14-16, derived from has been introduced, then the cells would have been added 90 Madin Darby canine kidney. The original MDCK cells are minutes from the start of transfection or 30 minutes after 45 available from the ATCC as CCL 34. It is preferred that transfection. derivatives of these cells or derivatives of other MDCK cells The number of cells which are added after transfection will are used. Derivatives of MDCK cells were described, for generally vary depending on the number of cells which are instance, in reference 14 which discloses MDCK cells that used as host cells for transfection and also on the size of the were adapted for growth in suspension culture (MDCK cell culture vessel which is used for transfection. The number 50 33016 or 33016-PF, deposited as DSMACC 2219; see also of cells which could be used in the methods of the invention ref. 14). Furthermore, reference 17 discloses MDCK-derived can be easily determined by the skilled person. For example, cells that grow in suspension in serum free culture (B-702, the methods of the invention can be performed under identical deposited as FERMBP-7449). The MDCK cell lineused may conditions in several parallel experiments except that the be tumorigenic. It is also envisioned to use non-tumorigenic number of cells which are added differs. The number of cells 55 MDCK cells. For example, reference 18 discloses non tum which gives the highest virus yield can be used in further origenic MDCK cells, including MDCK-S (ATCC PTA experiments. For example, when about 6x10 cells are used as 6500), MDCK-SF101 (ATCCPTA-6501), "MDCK-SF102 a starting culture for transfection with LipofectamineTM, (ATCC PTA-6502) and MDCK-SF103 (ATCC PTA-6503). about 4x10 cells can be added. Reference 19 discloses MDCK cells with high susceptibility The cells which are added after transfection provide a 60 to infection, including MDCK.5F1 cells (ATCC CRL substrate for the rescued virus to replicate on. Thus, the cells 12042). may be uninfected cells which means that the cells, within a The cells which are used for transfection and the cells certaintime (for example 48 hours) before they are used in the which are added after transfection may be of the same or of a methods of the invention, have not been infected with a virus different cell type. For example, the expression constructs or transfected with an expression construct encoding a viral 65 may be transfected into MDCK cells and the cells added may RNA. Cells which have been infected with a virus, for be Vero cells or vice versa. Another example may be methods example Epstein-Barr virus, to immortalize them are suitable where the expression constructs are transfected into one US 8,883,481 B2 7 8 strain of MDCK cells and the cells added are of a different usually grown at a temperature between 36°C. and 38°C., or MDCK strain. This approach is advantageous where the res about 37°C. This temperature is also chosen for the rescue of cued virus grows best in a cell line which can not easily be many viruses, even though some viruses, like influenza, may transfected. In this aspect, the virus can be transfected into be rescued at a temperature of about 33°C. as this can result cells which are more easily transfectable but can subse 5 in better antigenicity of the resulting virus 20. Suitable quently be propagated in a cell line which is better suited for temperatures can also be identified by performing several viral replication. However, it is generally preferred to use the transfection experiments in parallel under identical condi same cell line (e.g. MDCK33016 cells) as a host cell for both tions except that the incubation temperature after transfection transfection and for Subsequent addition of cells as this has varies. The temperature which results in the biggest number the advantage, for example, that competing culture selection 10 of PFUs can be used after transfection. Suitable methods for pressures or different cell culture conditions can be avoided. It is also possible to use a mixture of more than one cell type assaying for PFUs have been described above in relation to as host cells for transfection and/or for addition after trans assays for identifying temperatures which can be used during fection. transfection. Preferably, the cells are cultured in the absence of serum, to 15 Virus Preparation avoid a common Source of contaminants. Various serum-free In a further aspect, the present invention provides a method media for eukaryotic cell culture are known to the person of preparing a virus for vaccine manufacture, comprising the skilled in the art (e.g. Iscove’s medium, ultra CHO medium steps of (i) transfecting a culture of host cells with at least one (BioWhittaker), EX-CELL (JRH Biosciences)). Further expression construct encoding a viral RNA molecule; (ii) more, protein-free media may be used (e.g. PF-CHO (JRH adding cells to the transfected host cells of (i) to provide a Biosciences)). Otherwise, the cells for replication can also be mixture of cells; (iii) culturing the mixture of cells in order to cultured in the customary serum-containing media (e.g. produce virus; and (iv) purifying the virus obtained in step MEM or DMEM medium with 0.5% to 10% of fetal calf (iii) and optionally (V) formulating the virus into a vaccine. serum). Where cells are used as a culture host in this aspect of the The host cells and the cells which are added may be in 25 invention, it is known that cell culture conditions (e.g. tem adherent culture or in Suspension culture. For example, the perature, cell density, pH value, etc.) are variable over a wide cells which are used for transfection can be adherent cells and range Subject to the cell line and the virus employed and can the cells which are added after transfection can also be adher be adapted to the requirements of the application. The follow ent cells. When the cells which are added after transfection ing information therefore merely represents guidelines. are adherent cells, it will be evident that the cells will need to 30 As mentioned above, cells are preferably cultured in removed from the culture vessel on which they grow before serum-free or protein-free media. they are added to the transfected cells. This can be achieved, Multiplication of the cells can be conducted in accordance for example, with the help of a serine protease like trypsin. It with methods known to those of skill in the art. For example, is also possible to use Suspension cells as host cells for trans the cells can be cultivated in a perfusion system using ordi fection and adherent cells for addition after transfection and 35 nary Support methods like centrifugation or filtration. More Vice versa. over, the cells can be multiplied according to the invention in The methods of the invention are usually practised at the a fed-hatch system before infection. In the context of the temperatures which are commonly used in the art for the present invention, a culture system is referred to as a fed specific transfection method which is used. For example, batch system in which the cells are initially cultured in a batch when liposomes are used for transfection, the transfection 40 system and depletion of nutrients (or part of the nutrients) in reaction may initially be incubated at room temperature when the medium is compensated by controlled feeding of concen the DNA/liposome complex is first added (e.g. for about 30 trated nutrients. It can be advantageous to adjust the value of minutes), followed by incubation at about 37°C. for a speci the medium during multiplication of cells before infection to fied period oftime (for example about 24 hours). The methods a value between pH 6.6 and pH 7.8 and especially between a of the invention can be practised with any transfection method 45 value between pH 7.2 and pH 7.3. Culturing of cells prefer known in the art and the temperatures at which transfection ably occurs at a temperature between 30 and 40°C. In step should be performed are therefore known to the skilled per (iii), the cells are preferably cultured at a temperature of son. Alternatively, it is also possible to find suitable incuba between 30° C. and 36° C. or between 32° C. and 34° C. or at tion temperatures by performing several transfection experi about 33°C. This is particularly preferred where the method ments in parallel under identical conditions except that the 50 of the invention is used to produce influenza virus, as it has incubation temperature during transfection varies. The num been shown that incubation of infected cells in this tempera ber of rescued viruses is indicative of the efficiency of trans ture range results in production of a virus that results in fection and can be determined by assaying for the number of improved efficacy when formulated into a vaccine 20. PFUs produced, as described above. The temperature which The oxygen partial pressure can be adjusted during cultur results in the biggest number of PFUs can be used for trans 55 ing before infection preferably at a value between 25% and fection. 95% and especially at a value between 35% and 60%. The The temperature at which the cells are added to the trans values for the oxygen partial pressure stated in the context of fected cells and the temperature at which the resulting mix the invention are based on saturation of air. Infection of cells ture of cells is incubated may be the same or different com occurs at a cell density of preferably about 8-25x10 cells/ pared to the temperature used during transfection. The 60 mL, in the batch system or preferably about 5-20x10 cells/ temperature can depend on the cell line used for addition after mL in the perfusion system. The cells can be infected with a transfection and can also vary with the virus which is rescued viral dose (MOI value, “multiplicity of infection': corre using the methods of the invention. Suitable temperatures for sponds to the number of virus units per cell at the time of growing individual cell lines or rescuing particular viruses are infection) between 10 and 10, preferably between 0.0001 known in the art, however, and the skilled person can there 65 and 0.5. fore easily identify Suitable temperatures. For example, mam Virus may be grown on cells in adherent culture or in malian cell lines like Vero, Per.C6 and MDCK cell lines are suspension. Microcarrier cultures can be used. Microcarrier US 8,883,481 B2 10 cultures are considered adherent cultures. The cells may also enterovirus A (HEV-A), Human enterovirus B (HEV-B), be adapted for growth in Suspension. Human enterovirus C. Human enterovirus D, Hepatitis A and The methods according to the invention also include har Human rhinovirus A and B. vesting and isolation of viruses or the proteins generated by Where the virus is a double-stranded RNA virus, the virus them. During isolation of viruses or proteins, the cells are 5 may be from a family selected from the group consisting of separated from the culture medium by standard methods like Birnaviridae, Cystoviridae, Hypoviridae, Partitiviridae, separation, filtration or ultrafiltration. The viruses or the pro Reoviridae and Totiviridae. Furthermore, the virus may be a teins are then concentrated according to methods sufficiently virus from a genus selected from the group consisting of known to those skilled in the art, like gradient centrifugation, Aquabirnavirus, Avibirnavirus, Entomobimavirus, Cystovi 10 rus, Partitivirus, Alphacryptovirus, Betacryptovirus, Aquar filtration, precipitation, chromatography, etc., and then puri eovirus, Coltivirus, Cypovirus, Fijivirus, Idnoreovirus, fied. It is also preferred according to the invention that the Mycoreovirus, Orbivirus, Orthoreovirus, Oryzavirus, Phy viruses are inactivated during or after purification. Virus inac toreovirus, Rotavirus and Seadornavirus. tivation can occur, for example, by 3-propiolactone or form Preferred viruses for use with the invention are rotaviruses. aldehyde at any point within the purification process. 15 Reverse genetics with these viruses is currently difficult due The viruses isolated according to the invention, can also be to the poor efficiency of the viral rescue and the methods of grown on eggs in step (iii). The current standard method for the invention can therefore facilitate the rescue of this virus. influenza virus growth for vaccines uses embryonated SPF The present invention is also particularly suitable for hen eggs, with virus being purified from the egg contents viruses which undergo rapid mutation and where the recom (allantoic fluid). It is also possible to passage a virus through binant approach allows for a more rapid isolation of the virus eggs and Subsequently propagate it in cell culture. which can then be further propagated to obtain suitable vac Viruses cines. Therefore, in another preferred embodiment the virus The methods of the invention may be practised with any is influenza. virus which can be expressed by reverse genetics in a cell. Influenza Viruses Such viruses can be segmented or non-segmented viruses. 25 Influenza viruses are particularly suitable for use in the Furthermore, the virus can be a positive-strand RNA virus or methods of the present invention, particularly influenza A a negative-strand RNA virus. The virus may also be a double viruses and influenza B viruses, as reverse genetics for this stranded RNA virus. virus has been well characterized. Influenza viruses are seg Where the virus is a negative-strand RNA virus, the virus mented negative strand RNA viruses Influenza A and B may be from a family selected from the group consisting of 30 viruses have eight segments, whereas influenza C virus has seven. The virus requires at least four viral proteins (PB1, Paramyxoviridae, Pneumovirinae, Rhabdoviridae, Filoviri PB2, PA and nucleoprotein) to initiate replication and tran dae, Bornaviridae, Orthomyxoviridae, Bunyaviridae, or Scription. Arenaviridae. Furthermore, the virus may be a virus from a Reverse genetics for influenza A and B viruses can be genus selected from the group consisting of Paramyxovirus, 35 practised with 12 plasmids to express the four required pro Orthomyxovirus, Respirovirus, Morbillivirus, Rubulavirus, teins and all eight genome segments. To reduce the number of Henipaviras, AVulavirus, Pneumovirus, Metapneumovirus, constructs, however, a plurality of RNA polymerase I tran Vesiculovirus, Lyssavirus, Ephemerovirus, Cytorhabdovirus, scription cassettes (for viral RNA synthesis) can be included Nucleorhabdovirus, Novirhabdovirus, Marburgvirus, Ebo on a single plasmid (e.g. sequences encoding 1, 2, 3, 4, 5, 6, 7 lavirus, Bornavirus, Influenzavirus A, Influenzavirus B, 40 or all 8 influenza VRNA segments), and a plurality of protein Influenzavirus C, Thogotovirus, Isavirus, Orthobunyavirus, coding regions with RNA polymerase II promoters on Hantavirus, Nairovirus, Phlebovirus, Tospovirus, Arenavirus, another plasmid (e.g. sequences encoding 1, 2, 3, 4, 5, 6, 7 or Ophiovirus, Tenuivirus, or Deltavirus. In specific embodi 8 influenza mRNA transcripts) 21. It is also possible to ments, the negative-strand RNA virus is selected from the include one or more influenza vRNA segments under control group consisting of Sendai virus, Measles virus, Mumps 45 of a pol I promoter and one or more influenza protein coding virus, Hendra virus, Newcastle disease virus, Human respi regions under control of another promoter, in particular a pol ratory syncytial virus, Avian pneumovirus, Vesicular stoma II promoter, on the same plasmid. As described above, this is titis Indiana virus, Rabies virus, Bovine ephemeral fever preferably done by using bi-directional plasmids. virus, Lettuce necrotic yellows virus, Potato yellow dwarf Preferred aspects of the reference 21 method involve: (a) virus, Infectious hematopoietic necrosis virus, Lake Victoria 50 PB1, PB2 and PA mRNA-encoding regions on a single plas marburgvirus, Zaire ebolavirus, Borna disease virus, Influ mid; and (b) all 8 VRNA encoding segments on a single enza virus, Thogoto virus, Infectious Salmon anemia virus, plasmid. Including the neuraminidase (NA) and hemaggluti Bunyamwera virus, Hantaan virus, Dugbe virus, Rift Valley nin (HA) segments on one plasmid and the six other segments fever virus, Tomato spotted wilt virus, Lymphocytic chori on another plasmid is particularly preferred as newly emerg omeningitis virus, Citrus psorosis virus, Rice stripe virus, and 55 ing influenza virus strains usually have mutations in the NA Hepatitis delta virus. In preferred embodiments, the virus is and/or HA segments. Therefore, in this embodiment, only the an influenza virus (see below). vector comprising the HA and NA sequence needs to be Where the virus is a positive-strand RNA virus, the virus replaced. may be from a family selected from the group consisting of Preferred expression systems for influenza A viruses Arteriviridae, Coronaviridae, Picornaviridae and Roniviri 60 encode genome segments derived from a plurality of different dae. Furthermore, the virus may be a virus from a genus wild-type strains. The system may encode 1 or more (e.g. 1, 2, selected from the group consisting of Artetivirius, Coronavi 3, 4, 5 or 6) genome segments from a PR/8/34 strain (A/Pu rus, Enterovirus, Torovirus, Okavirus, Rhinovirus, Hepatovi erto Rico/8/34), but usually this/these will not include the rus, Cardiovirus, Aphthovirus, Parechovirus, Erbovirus, PR/8/34HA segment and usually will not include the PR/8/34 Kobuvirus and Teschovirus. In specific embodiments, the 65 NA segment. Thus the system may encode at least one of virus is selected from the group consisting of severe acute segments NP. M, NS, PA, PB1 and/or PB2 (possibly all six) respiratory syndrome (SARS) virus, polio virus, Human from PRA8/34. US 8,883,481 B2 11 12 Other useful expression systems for influenza A viruses ethylammonium bromide, Tergitol NP9, etc.) to produce sub may encode 1 or more (e.g. 1, 2, 3, 4, 5 or 6) genome segments virion preparations, including the Tween-ether splitting pro from an AA/6/60 influenza virus (A/Ann Arbor/6/60), but cess. Methods of splitting influenza viruses, for example are usually this/these will not include the AA/6/60 HA segment well known in the art e.g. see refs. 22-27, etc. Splitting of the and usually will not include the AA/6/60 NA segment. Thus virus is typically carried out by disrupting or fragmenting the system may encode at least one of segments NP. M, NS, whole virus, whether infectious or non-infectious with a dis PA, PB1 and/or PB2 (possibly all six) from AA/6/60. rupting concentration of a splitting agent. The disruption The system may encode 1 or more genome segments from results in a full or partial solubilisation of the virus proteins, an A/California/4/09 strain e.g. the HA segment and/or the altering the integrity of the virus. Preferred splitting agents NA segment. Thus, for instance, the HA gene segment may 10 are non-ionic and ionic (e.g. cationic) Surfactants e.g. alkylg encode a H1 hemagglutinin which is more closely related to lycosides, alkyithioglycosides, acyl Sugars, Sulphobetaines, SEQID NO: 1 than to SEQID NO: 2 (i.e. has a higher degree betains, polyoxyethylenealkylethers, N,N-dialkyl-Glucam sequence identity when compared to SEQID NO: 1 than to ides, Hecameg, alkylphenoxy-polyethoxyethanols, NP9, SEQ ID NO: 2 using the same algorithm and parameters). quaternary ammonium compounds, sarcosyl, CTABS (cetyl SEQ ID NOs: 1 and 2 are 80% identical. Similarly, the NA 15 trimethyl ammonium bromides), tri-N-butyl phosphate, gene may encode a N1 neuraminidase which is more closely Cetavlon, myristyltrimethylammonium salts, lipofectin, lipo related to SEQID NO:3 than to SEQID NO:4. SEQID NOs: fectamine, and DOT-MA, the octyl- or nonylphenoxy poly 3 and 4 are 82% identical. oxyethanols (e.g. the Triton surfactants, such as Triton X-100 Expression systems for influenza B viruses may encode or Triton N101), polyoxyethylene sorbitan esters (the Tween genome segments derived from a plurality of different wild Surfactants), polyoxyethylene ethers, polyoxyethlene esters, type strains. The system may encode 1 or more (e.g. 1, 2, 3, 4, etc. One useful splitting procedure uses the consecutive 5 or 6) genome segments from a AA/1/66 influenza virus effects of sodium deoxycholate and formaldehyde, and split (B/Ann Arbor/1/66), but usually this/these will not include ting can take place during initial virion purification (e.g. in a the AA/1/66 HA segment and usually will not include the Sucrose density gradient solution). Thus a splitting process AA/1/66 NA segment. Thus the system may encode at least 25 can involve clarification of the virion-containing material (to one of segments NP. M, NS, PA, PB1 and/or PB2 from AA/1/ remove non-virion material), concentration of the harvested 66. virions (e.g. using an adsorption method, such as CaHPO Viral segments and sequences from the A/PR/8/34, AA/6/ adsorption), separation of whole virions from non-virion 60, AA/1/66, A/Chile/1/83 and A/California/04/09 strains are material, splitting of virions using a splitting agent in a den widely available. Their sequences are available on the public 30 sity gradient centrifugation step (e.g. using a Sucrose gradient databases e.g. GI:8977.9337, GI:89779334, GI:89779332, that contains a splitting agent such as sodium deoxycholate), GI:89779320, GI:89779327, GI:897.79325, GI:89779322, and then filtration (e.g. ultrafiltration) to remove undesired GI:897793.29. materials. Split virions can usefully be resuspended in Sodium A reverse genetics system for influenza virus may include phosphate-buffered isotonic sodium chloride solution. an expression construct which leads to expression of an 35 Examples of split influenza vaccines are the BEGRIVACTM, accessory protein in the host cell. For instance, it can be FLUARIXTM, FLUZONETM and FLUSHIELDTM products. advantageous to express a non-viral serine protease (e.g. The method of the invention may also be used to produce trypsin). live vaccines. Such vaccines are usually prepared by purify Vaccine ing virions from virion-containing fluids. For example, the In one aspect, the invention utilises virus produced accord 40 fluids may be clarified by centrifugation, and stabilized with ing to the methods of the invention to produce vaccines. buffer (e.g. containing Sucrose, potassium phosphate, and Vaccines (particularly for influenza virus) are generally monosodium glutamate). Various forms of influenza virus based either on live virus or on inactivated virus. Inactivated vaccine are currently available (e.g. see chapters 17 & 18 of vaccines may be based on whole virions, split virions, or on reference 28). Live viruses include MedImmune's FLU purified Surface antigens. Antigens can also be presented in 45 MISTTM product (trivalent live virus). the form of Virosomes. The invention can be used for manu Purified influenza virus Surface antigen vaccines comprise facturing any of these types of vaccine. the Surface antigens hemagglutinin and, typically, also Where an inactivated virus is used, the vaccine may com neuraminidase. Processes for preparing these proteins in prise whole virion, split virion, or purified Surface antigens purified form are well known in the art. The FLUVIRINTM, (for influenza, including hemagglutinin and, usually, also 50 AGRIPPALTM and INFLUVACTM products are influenza sub including neuraminidase). Chemical means for inactivating a unit vaccines. virus include treatment with an effective amount of one or Another form of inactivated antigen is the virosome 29 more of the following agents: detergents, formaldehyde, (nucleic acid free viral-like liposomal particles). Virosomes B-propiolactone, methylene blue, psoralen, carboxyfullerene can be prepared by solubilization of virus with a detergent (C60), binary ethylamine, acetyl ethyleneimine, or combina 55 followed by removal of the nucleocapsid and reconstitution tions thereof. Non-chemical methods of viral inactivation are of the membrane containing the viral glycoproteins. An alter known in the art, Such as for example UV light or gamma native method for preparing Virosomes involves adding viral irradiation. membrane glycoproteins to excess amounts of phospholip Virions can be harvested from virus-containing fluids, e.g. ids, to give liposomes with viral proteins in their membrane. allantoic fluid or cell culture Supernatant, by various methods. 60 The virus may be attenuated. The virus may be tempera For example, a purification process may involve Zonal cen ture-sensitive. The virus may be cold-adapted. These three trifugation using a linear Sucrose gradient Solution that features are particularly useful when using live virus as an includes detergent to disrupt the virions. Antigens may then antigen. be purified, after optional dilution, by diafiltration. HA is the main immunogen in current inactivated influenza Split virions are obtained by treating purified virions with 65 vaccines, and vaccine doses are standardised by reference to detergents (e.g. ethyl ether, polysorbate 80, deoxycholate, HA levels, typically measured by SRID. Existing vaccines tri-N-butyl phosphate, Triton X-100, Triton N101, cetyltrim typically contain about 15ug of HA per strain, although lower US 8,883,481 B2 13 14 doses can be used e.g. for children, or in pandemic situations, vaccine includes more than one strain of influenza, the dif or when using an adjuvant. Fractional doses such as /2 (i.e. ferent strains are typically grown separately and are mixed 7.5ug HA per Strain), 4 and /s have been used, as have higher after the viruses have been harvested and antigens have been doses (e.g. 3x or 9x doses 30.31). Thus vaccines may prepared. Thus a process of the invention may include the step include between 0.1 and 150 ug of HA per influenza strain, of mixing antigens from more than one influenza strain. A preferably between 0.1 and 50 ug e.g. 0.1-20 lug, 0.1-15 lug, trivalent vaccine is typical, including antigens from two influ 0.1-10 ug, 0.1-7.5ug, 0.5-5 ug, etc. Particular doses include enza A virus strains and one influenza B virus Strain. A tet e.g. about 45, about 30, about 15, about 10, about 7.5, about ravalent vaccine is also useful 34, including antigens from 5, about 3.8, about 3.75, about 1.9, about 1.5, etc. per strain. two influenza A virus strains and two influenza B virus For live vaccines, dosing is measured by median tissue 10 strains, or three influenza A virus strains and one influenza B culture infectious dose (TCIDs) rather than HA content, and virus strain. a TCIDs of between 10° and 10 (preferably between 10 Pharmaceutical Compositions 107) per strain is typical. Vaccine compositions manufactured according to the Influenza strains used with the invention may have a natu invention are pharmaceutically acceptable. They usually ral HA as found in a wild-type virus, or a modified HA. For 15 include components in addition to the antigens e.g. they typi instance, it is known to modify HA to remove determinants cally include one or more pharmaceutical carrier(s) and/or (e.g. hyper-basic regions around the HA1/HA2 cleavage site) excipient(s). As described below, adjuvants may also be that cause a virus to be highly pathogenic in avian species. included. A thorough discussion of Such components is avail The use of reverse genetics facilitates Such modifications. able in reference 35. Influenza virus strains for use in vaccines change from Vaccine compositions will generally be in aqueous form. season to season. In inter-pandemic periods, vaccines typi However, some vaccines may be in dry form, e.g. in the form cally include two influenza A strains (H1N1 and H3N2) and of injectable Solids or dried or polymerized preparations on a one influenza B strain, and trivalent vaccines are typical. The patch. invention may also use pandemic viral strains (i.e. strains to Vaccine compositions may include preservatives such as which the vaccine recipient and the general human population 25 thiomersal or 2-phenoxyethanol. It is preferred, however, that are immunologically naive, in particular of influenza A the vaccine should be substantially free from (i.e. less than 5 virus), such as H2, H5, H7 or H9 subtype strains, and influ ug/ml) mercurial material e.g. thiomersal-free 26.36. Vac enza vaccines for pandemic strains may be monovalent or cines containing no mercury are more preferred, C.-toco may be based on a normal trivalent vaccine Supplemented by pherol Succinate can be included as an alternative to mercurial a pandemic strain. Depending on the season and on the nature 30 compounds 26. Preservative-free vaccines are particularly of the antigen included in the vaccine, however, the invention preferred. may protect againstone or more of HA subtypes H1, H2,H3. To control tonicity, it is preferred to include a physiological H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15 or salt, such as a sodium salt. Sodium chloride (NaCl) is pre H16. The invention may protect against one or more of influ ferred, which may be present at between 1 and 20 mg/ml. enza A virus NA subtypes N1, N2, N3, N4, N5, N6, N7, N8 or 35 Other salts that may be present include potassium chloride, N9. potassium dihydrogen phosphate, disodium phosphate dehy As well as being Suitable for immunizing against inter drate, magnesium chloride, calcium chloride, etc. pandemic strains, the compositions of the invention are par Vaccine compositions will generally have an osmolality of ticularly useful for immunizing against pandemic or poten between 200 mOsm/kg and 400 mOsm/kg, preferably tially-pandemic strains. The characteristics of an influenza 40 between 240-360 mOsm/kg, and will more preferably fall strain that give it the potential to cause a pandemic outbreak within the range of 290-310 mCsm/kg. Osmolality has pre are: (a) it contains a new hemagglutinin compared to the viously been reported not to have an impact on pain caused by hemagglutinins in currently-circulating human strains, i.e. vaccination 37, but keeping osmolality in this range is nev one that has not been evident in the human population for over ertheless preferred. a decade (e.g. H2), or has not previously been seen at all in the 45 Vaccine compositions may include one or more buffers. human population (e.g. H5, H6 or H9, that have generally Typical buffers include: a phosphate buffer; a Tris buffer; a been found only in bird populations). Such that the human borate buffer; a succinate buffer; a histidine buffer (particu population will be immunologically naive to the Strain's larly with an aluminum hydroxide adjuvant); or a citrate hemagglutinin; (b) it is capable of being transmitted horizon buffer. Buffers will typically be included in the 5-20 mM tally in the human population; and (c) it is pathogenic to 50 range. humans. A virus with H5 hemagglutinin type is preferred for The pH of a vaccine composition will generally be between immunizing against pandemic influenza, Such as a H5N1 5.0 and 8.1, and more typically between 6.0 and 8.0 e.g. 6.5 strain. Other possible strains include H5N3, H9N2, H2N2, and 7.5, or between 7.0 and 7.8. A process of the invention H7N1 and H7N7, and any other emerging potentially pan may therefore include a step of adjusting the pH of the bulk demic strains. The invention is particularly suitable for pro 55 Vaccine prior to packaging. tecting against potential pandemic virus strains that can or The vaccine composition is preferably sterile. The vaccine have spread from a non-human animal population to humans, composition is preferably non-pyrogenic e.g. containing <1 for example a swine-origin H1N1 influenza strain. The inven EU (endotoxin unit, a standard measure) per dose, and pref tion is then Suitable for vaccinating humans as well as non erably <0.1 EU per dose. The vaccine composition is prefer human animals. 60 ably gluten-free. Other strains whose antigens can usefully be included in Vaccine compositions of the invention may include deter the compositions are strains which are resistant to antiviral gent e.g. a polyoxyethylene Sorbitan ester Surfactant (known therapy (e.g. resistant to oseltamivir 32 and/or Zanamivir), as Tweens), an octoxynol (Such as octoxynol-9 (Triton including resistant pandemic strains 33. X-100) or t-octylphenoxypolyethoxyethanol), a cetyl trim Compositions of the invention may include antigenCS) from 65 ethyl ammonium bromide (CTAB), or sodium deoxycho one or more (e.g. 1, 2, 3, 4 or more) influenza virus strains, late, particularly for a split or Surface antigen vaccine. The including influenza A virus and/or influenza B virus. Where a detergent may be present only at trace amounts. Thus the US 8,883,481 B2 15 16 vaccine may included less than 1 mg/ml of each of octoxynol naturally in seed oils, may be prepared by hydrolysis, sepa 10 and polysorbate 80. Other residual components in trace ration and esterification of the appropriate materials starting amounts could be antibiotics (e.g. neomycin, kanamycin, from the nut and seed oils. Fats and oils from mammalian polymyxin B). milk are metabolizable and may therefore be used in the A vaccine composition may include material for a single practice of this invention. The procedures for separation, immunisation, or may include material for multiple immuni purification, Saponification and other means necessary for sations (i.e. a multidose kit). The inclusion of a preservative obtaining pure oils from animal sources are well known in the is preferred in multidose arrangements. As an alternative (or art. Most fish contain metabolizable oils which may be in addition) to including a preservative in multidose compo readily recovered. For example, cod liver oil, shark liver oils, sitions, the compositions may be contained in a container 10 and whale oil such as spermaceti exemplify several of the fish having an aseptic adaptor for removal of material. oils which may be used herein. A number of branched chain Influenza vaccines are typically administered in a dosage oils are synthesized biochemically in 5-carbon isoprene units volume of about 0.5 ml, although a half dose (i.e. about 0.25 and are generally referred to as terpenoids. Shark liver oil ml) may be administered to children. contains a branched, unsaturated terpenoids known as Compositions and kits are preferably stored at between 2 15 squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14, 18.22-tet C. and 8°C. They should not be frozen. They should ideally racosahexaene, which is particularly preferred herein. be kept out of direct light. Squalane, the saturated analog to squalene, is also a preferred Host Cell DNA oil. Fish oils, including squalene and squalane, are readily Where virus has been isolated and/or grown on a cell line, available from commercial sources or may be obtained by it is standard practice to minimize the amount of residual cell methods known in the art. Another preferred oil is C.-toco line DNA in the final vaccine, in order to minimize any pherol (see below). oncogenic activity of the DNA. Mixtures of Oils can be Used. Thus a vaccine composition prepared according to the Surfactants can be classified by their HLB (hydrophile/ invention preferably contains less than 10 ng (preferably less lipophile balance). Preferred surfactants of the invention have than 1 ng, and more preferably less than 100 pg) of residual 25 a HLB of at least 10, preferably at least 15, and more prefer host cell DNA per dose, although trace amounts of host cell ably at least 16. The invention can be used with surfactants DNA may be present. including, but not limited to: the polyoxyethylene sorbitan It is preferred that the average length of any residual host esters Surfactants (commonly referred to as the Tweens), cell DNA is less than 500 bp e.g. less than 400 bp, less than especially polysorbate 20 and polysorbate 80; copolymers of 300 bp, less than 200 bp, less than 100 bp, etc. 30 ethylene oxide (EO), propylene oxide (PO), and/or butylene Contaminating DNA can be removed during vaccine oxide (BO), sold under the DOWFAXTM tradename, such as preparation using standard purification procedures e.g. chro linear EO/PO block copolymers; octoxynols, which can vary matography, etc. Removal of residual host cell DNA can be in the number of repeating ethoxy (oxy-1,2-ethanediyl) enhanced by nuclease treatment e.g. by using a DNase. A groups, with octoxynol-9 (Triton X-100, or t-octylphenoxy convenient method for reducing host cell DNA contamina 35 polyethoxyethanol) being of particular interest, (octylphe tion is disclosed in references 38 & 39, involving a two-step noxy)polyethoxyethanol (IGEPAL CA-630/NP-40): phos treatment, first using a DNase (e.g. BenZonase), which may pholipids such as phosphatidylcholine (lecithin); be used during viral growth, and then a cationic detergent nonylphenol ethoxylates, such as the TergitolTM NP series: (e.g. CTAB), which may be used during virion disruption. polyoxyethylene fatty ethers derived from lauryl, cetyl, Treatment with an alkylating agent, such as B-propiolactone, 40 Stearylandoleyl alcohols (known as BrijSurfactants), Such as can also be used to remove host cell DNA, and advanta triethyleneglycol monolauryl ether (Brij 30); and sorbitan geously may also be used to inactivate virions 40. esters (commonly known as the SPANs), such as sorbitan Adjuvants trioleate (Span 85) and sorbitan monolaurate. Non-ionic sur Compositions of the invention may advantageously factants are preferred. Preferred surfactants for including in include an adjuvant, which can function to enhance the 45 the emulsion are Tween 80 (polyoxyethylene sorbitan immune responses (humoral and/or cellular) elicited in a monooleate), Span 85 (sorbitan trioleate), lecithin and Triton subject who receives the composition. Preferred adjuvants X-100. comprise oil-in-water emulsions. Various such adjuvants are Mixtures of surfactants can be used e.g. Tween 80/Span 85 known, and they typically include at least one oil and at least mixtures. A combination of a polyoxyethylene Sorbitan ester one Surfactant, with the oil(s) and Surfactant(s) being biode 50 such as polyoxyethylene sorbitan monooleate (Tween 80) gradable (metabolisable) and biocompatible. The oil droplets and an octoxynol Such as t-octylphenoxypolyethoxyethanol in the emulsion are generally less than 5um in diameter, and (Triton X-100) is also suitable. Another useful combination ideally have a sub-micron diameter, with these small sizes comprises laureth 9 plus a polyoxyethylene Sorbitan ester being achieved with a microfluidiser to provide stable emul and/or an octoxynol. sions. Droplets with a size less than 220 nm are preferred as 55 Preferred amounts of surfactants (% by weight) are: poly they can be subjected to filter sterilization. oxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in The emulsion can comprise oils such as those from an particular about 0.1%; octyl- or nonylphenoxy polyoxyetha animal (Such as fish) or vegetable source. Sources for Veg nols (such as Triton X-100, or other detergents in the Triton etable oils include nuts, seeds and grains. Peanut oil, soybean series) 0.001 to 0.1%, in particular 0.005 to 0.02%; polyoxy oil, coconut oil, and olive oil, the most commonly available, 60 ethylene ethers (such as laureth9) 0.1 to 20%, preferably 0.1 exemplify the nut oils. Jojoba oil can be used e.g. obtained to 10% and in particular 0.1 to 1% or about 0.5%. from the jojoba bean. Seed oils include safflower oil, cotton Where the vaccine contains a split virus, it is preferred that seed oil, Sunflower seed oil, sesame seed oil and the like. In it contains free Surfactant in the aqueous phase. This is advan the grain group, corn oil is the most readily available, but the tageous as the free surfactant can exert a splitting effect on oil of other cereal grains such as wheat, oats, rye, rice, teff, 65 the antigen, thereby disrupting any unsplit virions and/or triticale and the like may also be used, 6-10 carbon fatty acid virion aggregates that might otherwise be present. This can esters of glycerol and 1.2-propanediol, while not occurring improve the safety of split virus vaccines 41. US 8,883,481 B2 17 18 Preferred emulsions have an average droplets size of <1 um or has at least 90% of the oil droplets (by volume) with e.g. s750 nm, s500 nm, s400 nm, s300 nm, s250 nm, s220 a size less than 200 nm 50. The emulsion may also nm, or s200 nm, or Smaller. These droplet sizes can conve include one or more of alditol; a cryoprotective agent niently be achieved by techniques such as microfluidisation. (e.g. a Sugar, Such as dodecylmaltoside and/or Sucrose); Specific oil-in-water emulsion adjuvants useful with the and/or an alkylpolyglycoside. The emulsion may invention include, but are not limited to: include a TLR4 agonist 51. Such emulsions may be A submicron emulsion of squalene, Tween 80, and Span lyophilized 85. The composition of the emulsion by volume can be An emulsion of squalene, poloxamer 105 and Abil-Care about 5% squalene, about 0.5% polysorbate 80 and 52. The final concentration (weight) of these compo about 0.5% Span 85. In weight terms, these ratios 10 become 4.3% squalene, 0.5% polysorbate 80 and 0.48% nents in adjuvanted vaccines are 5% squalene, 4% Span 85. This adjuvant is known as MF5942-44, as poloxamer 105 (pluronic polyol) and 2% Abil-Care 85 described in more detail in Chapter 10 of ref. 45 and (Bis-PEG/PPG-16/16 PEG/PPG-16/16 dimethicone; chapter 12 of ref. 46. The MF59 emulsion advanta caprylic/capric triglyceride). geously includes citrate ions e.g. 10 mM sodium citrate 15 An emulsion having from 0.5-50% of an oil, 0.1-10% of a buffer. phospholipid, and 0.05-5% of a non-ionic surfactant. As An emulsion of squalene, DL-C-tocopherol, and polysor described in reference 53, preferred phospholipid com bate 80 (Tween 80). The emulsion may include phos ponents are phosphatidylcholine, phosphatidylethano phate buffered saline. It may also include Span 85 (e.g. lamine, phosphatidylserine, phosphatidylinositol, phos at 1%) and/or lecithin. These emulsions may have from phatidylglycerol, phosphatidic acid, sphingomyelin and 2 to 10% squalene, from 2 to 10% tocopherol and from cardiolipin. Submicron droplet sizes are advantageous. 0.3 to 3% Tween 80, and the weight ratio of squalene: A submieron oil-in-water emulsion of a non-metabolisable tocopherol is preferably s1 as this provides a more stable oil (such as light mineral oil) and at least one surfactant emulsion. Squalene and Tween 80 may be present vol (such as lecithin, Tween 80 or Span 80). Additives may ume ratio of about 5:2 or at a weight ratio of about 11:5, 25 be included, such as QuilA saponin, cholesterol, a Sapo One such emulsion can be made by dissolving Tween 80 nin-lipophile conjugate (such as GPI-0100, described in in PBS to give a 2% solution, then mixing 90 ml of this reference 54, produced by addition of aliphatic amine to solution with a mixture of (5 g of DL-C.-tocopherol and desacylsaponin via the carboxyl group of glucuronic 5 ml squalene), then microfluidising the mixture. The acid), dimethyldioctadecylammonium bromide and/or resulting emulsion may have submicron oil droplets e.g. 30 N,N-dioctadecyl-N,N-bis(2-hydroxyethyl)propanedi with an average diameter of between 100 and 250 nm, amine. preferably about 180 nm. The emulsion may also An emulsion in which a saponin (e.g. QuilA or QS21) and include a 3-de-O-acylated monophosphoryl lipid A (3d a sterol (e.g. a cholesterol) are associated as helical MPL). Another useful emulsion of this type may com micelles 55. prise, per human dose, 0.5-10 mg squalene, 0.5-11 mg 35 An emulsion comprising a mineral oil, a non-ionic lipo tocopherol, and 0.1-4 mg polysorbate 8047. philic ethoxylated fatty alcohol, and a non-ionic hydro An emulsion of squalene, a tocopherol, and a Triton deter philic Surfactant (e.g. an ethoxylated fatty alcohol and/or gent (e.g. Triton X-100). The emulsion may also include polyoxyethylene-polyoxypropylene block copolymer) a 3d-MPL (see below). The emulsion may contain a 56). phosphate buffer. 40 An emulsion comprising a mineral oil, a non-ionic hydro An emulsion comprising a polysorbate (e.g. polysorbate philic ethoxylated fatty alcohol, and a non-ionic lipo 80), a Triton detergent (e.g. Triton X-100) and a toco philic Surfactant (e.g. an ethoxylated fatty alcohol and/or pherol (e.g. an O-tocopherol Succinate). The emulsion polyoxyethylene-polyoxypropylene block copolymer) may include these three components at a mass ratio of 56). about 75:11:10 (e.g. 750 ug/ml polysorbate 80, 110 45 In some embodiments an emulsion may be mixed with ug/ml Triton X-100 and 100 g/ml C-tocopherol succi antigen extemporaneously, at the time of delivery, and thus nate), and these concentrations should include any con the adjuvantandantigen may be kept separately in a packaged tribution of these components from antigens. The emul or distributed vaccine, ready for final formulation at the time sion may also include squalene. The emulsion may also of use. In other embodiments an emulsion is mixed with include a 3d-MPL (see below). The aqueous phase may 50 antigen during manufacture, and thus the composition is contain a phosphate buffer. packaged in a liquid adjuvanted form. The antigen will gen An emulsion of squalane, polysorbate 80 and poloxamer erally be in an aqueous form, such that the vaccine is finally 401 ("PluronicTM L121). The emulsion can be formu prepared by mixing two liquids. The volume ratio of the two lated in phosphate buffered saline, pH 7.4. This emul liquids for mixing can vary (e.g. between 5:1 and 1:5) but is sion is a useful delivery vehicle for muramyl dipeptides, 55 generally about 1:1. Where concentrations of components are and has been used with threonyl-MDP in the “SAF-1” given in the above descriptions of specific emulsions, these adjuvant 48 (0.05-1% Thr-MDP, 5% squalane, 2.5% concentrations are typically for an undiluted composition, Pluronic L121 and 0.2% polysorbate 80). It can also be and the concentration after mixing with an antigen Solution used without the Thr-MDP, as in the “AF' adjuvant 49 will thus decrease. (5% squalane, 1.25% Pluronic L121 and 0.2% polysor 60 Packaging of Vaccine Compositions bate 80). Microfluidisation is preferred. Suitable containers for compositions of the invention (or An emulsion comprising squalene, an aqueous solvent, a kit components) include Vials, Syringes (e.g. disposable polyoxyethylene alkyl ether hydrophilic nonionic Sur Syringes), nasal sprays, etc. These containers should be ster factant (e.g. polyoxyethylene (12) cetostearyl ether) and ille. a hydrophobic nonionic Surfactant (e.g. a Sorbitan ester 65 Where a composition/component is located in a vial, the or mannide ester, Such as Sorbitan monoleate or Span vial is preferably made of a glass or plastic material. The vial 80). The emulsion is preferably thermoreversible and/ is preferably sterilized, before the composition is added to it. US 8,883,481 B2 19 20 To avoid problems with latex-sensitive patients, vials are 30-40 gives around 50% protection from infection by a preferably sealed with a latex-free stopper, and the absence of homologous virus) 57. Antibody responses are typically latex in all packaging material is preferred. The vial may measured by hemagglutination inhibition, by microneutrali include a single dose of vaccine, or it may include more than sation, by single radial immunodiffusion (SRID), and/or by one dose (a multidose vial) e.g. 10 doses. Preferred vials are 5 single radial hemolysis (SRH). These assay techniques are made of colourless glass. well known in the art. A vial can have a cap (e.g. a Luer lock) adapted Such that a Compositions of the invention can be administered in vari pie-filled Syringe can be inserted into the cap, the contents of ous ways. The most preferred immunisation route is by intra the Syringe can be expelled into the vial (e.g. to reconstitute muscular injection (e.g. into the arm or leg), but other avail lyophilised material therein), and the contents of the vial can 10 able routes include Subcutaneous injection, intranasal 58 be removed back into the syringe. After removal of the 60, oral 61, intradermal 62,63, transcutaneous, Syringe from the vial, a needle can then be attached and the transdermal 64, etc. composition can be administered to a patient. The cap is Vaccines prepared according to the invention may be used preferably located inside a seal or cover, such that the seal or to treat both children and adults. Influenza vaccines are cur cover has to be removed before the cap can be accessed. A vial 15 may have a cap that permits aseptic removal of its contents, rently recommended for use in pediatric and adult immuni particularly for multidose vials. sation, from the age of 6 months. Thus a human Subject may Where a component is packaged into a syringe, the Syringe be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 may have a needle attached to it. If a needle is not attached, a years old, or at least 55 years old. Preferred subjects for separate needle may be supplied with the Syringe for assem receiving the vaccines are the elderly (e.g. 250 years old, a 60 bly and use. Such a needle may be sheathed. Safety needles years old, and preferably a 65 years), the young (e.g. s.5 years are preferred. 1-inch 23-gauge, 1-inch 25-gauge and 5/8-inch old), hospitalised Subjects, healthcare workers, armed service 25-gauge needles are typical. Syringes may be provided with and military personnel, pregnant women, the chronically ill, peel-off labels on which the lot number, influenza season and immunodeficient Subjects, subjects who have taken an anti expiration date of the contents may be printed, to facilitate 25 viral compound (e.g. an oseltamivir or Zanamivir compound; record keeping. The plunger in the Syringe preferably has a see below) in the 7 days prior to receiving the vaccine, people stopper to prevent the plunger from being accidentally with egg allergies and people travelling abroad. The vaccines removed during aspiration. The Syringes may have a latex are not suitable solely for these groups, however, and may be rubber cap and/or plunger. Disposable Syringes contain a used more generally in a population. For pandemic strains, single dose of vaccine. The Syringe will generally have a tip 30 administration to all age groups is preferred. cap to seal the tip prior to attachment of a needle, and the tip Preferred compositions of the invention satisfy 1, 2 or 3 of cap is preferably made of a butyl rubber. If the syringe and the CPMP criteria for efficacy. In adults (18-60 years), these needle are packaged separately then the needle is preferably criteria are: (1) >70% seroprotection; (2) >40% seroconver fitted with a butyl rubber shield. Preferred syringes are those sion; and/or (3) a GMT increase of >2.5-fold. In elderly (>60 marketed under the trade name "Tip-Lok'TM. 35 years), these criteria are: (1) >60% seroprotection; (2) >30% Containers may be marked to show a half-dose Volume e.g. seroconversion; and/or (3) a GMT increase of >2-fold. These to facilitate delivery to children. For instance, a syringe con criteria are based on open label studies with at least 50 taining a 0.5 ml dose may have a mark showing a 0.25 ml patients. Volume. Treatment can be by a single dose schedule or a multiple Where a glass container (e.g. a syringe or a vial) is used, 40 dose schedule. Multiple doses may be used in a primary then it is preferred to use a container made from a borosilicate immunisation schedule and/or in a booster immunisation glass rather than from a Soda lime glass. schedule. In a multiple dose schedule the various doses may A kit or composition may be packaged (e.g. In the same be given by the same or different routes e.g. a parenteral prime box) with a leaflet including details of the vaccine e.g. instruc and mucosal boost, a mucosal prime and parenteral boost, etc. tions for administration, details of the antigens within the 45 Administration of more than one dose (typically two doses) is vaccine, etc. The instructions may also contain warnings e.g. particularly useful in immunologically naive patients e.g. for to keep a solution of adrenaline readily available in case of people who have never received an influenza vaccine before, anaphylactic reaction following vaccination, etc. or for vaccinating against a new HA subtype (as in a pandemic Methods of Treatment, and Administration of the Vaccine outbreak). Multiple doses will typically be administered at The invention provides a vaccine manufactured according 50 least 1 week apart (e.g. about 2 weeks, about 3 weeks, about to the invention. These vaccine compositions are Suitable for 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, administration to human or non-human animal Subjects. Such about 12 weeks, about 16 weeks, etc.). as pigs, and the invention provides a method of raising an Vaccines produced by the invention may be administered immune response in a Subject, comprising the step of admin to patients at Substantially the same time as (e.g. during the istering a composition of the invention to the Subject. The 55 same medical consultation or visit to a healthcare profes invention also provides a composition of the invention for use sional or vaccination centre) other vaccines e.g. at Substan as a medicament, and provides the use of a composition of the tially the same time as a measles vaccine, a mumps vaccine, a invention for the manufacture of a medicament for raising an rubella vaccine, a MMR vaccine, a varicella vaccine, a immune response in a Subject. MMRV vaccine, a diphtheria vaccine, a tetanus vaccine, a The immune response raised by these methods and uses 60 pertussis vaccine, a DTP vaccine, a conjugated H. influenzae will generally include an antibody response, preferably a type b vaccine, an inactivated poliovirus vaccine, a hepatitis B protective antibody response. Methods for assessing antibody virus vaccine, a meningococcal conjugate vaccine (such as a responses, neutralising capability and protection after influ tetravalent A-C-W 135-Y vaccine), a respiratory syncytial enza virus vaccination are well known in the art. Human virus vaccine, a pneumococcal conjugate vaccine, etc. studies have shown that antibody titers against hemagglutinin 65 Administration at Substantially the same time as a pneumo of human influenza virus are correlated with protection (a coccal vaccine and/or ameningococcal vaccine is particularly serum sample hemagglutination-inhibition titer of about useful in elderly patients. US 8,883,481 B2 21 22 Similarly, vaccines of the invention may be administered to FFU/mL, the open boxes show results with PR8-WSN and patients at Substantially the same time as (e.g. during the same 5% Serum and the hatched boxes show results with PR8-WSN medical consultation or visit to a healthcare professional) an and no serum; A indicates that fresh uninfected cells were antiviral compound, and in particular an antiviral compound added; B indicates that no fresh uninfected cells were added. active against influenza virus (e.g. oseltamivir and/or Zan amivir). These antivirals include neuraminidase inhibitors, MODES FOR CARRYING OUT THE INVENTION such as a (3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpro poxy)-1-cyclohexene-1-carboxylic acid or 5-(acetylamino)- Viral Rescue 4-(aminoiminomethyl)-amino-2,6-anhydro-3,4,5- MDCK33016 cells were cultured in suspension in CDM trideoxy-D-glycero-D-galactonon-2-enonic acid, including 10 media at a temperature of 37° C. A day before transfection esters thereof (e.g. the ethyl esters) and salts thereof (e.g. the 6x10 cells/well were seeded in a CELL-BINDTM 6 well dish phosphate salts). A preferred antiviral is (3R,4R,5S)-4-acety in 2 mL DMEM medium with 5% FCS. In a parallel experi lamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-car ment the cells were seeded in the absence of FCS. The cells boxylic acid, ethyl ester, phosphate (1:1), also known as osel were incubated at 37° C. overnight. tamivir phosphate (TAMIFLUTM). 15 The next day the seeded cells were transfected with Lipo General fectamineTMLTX Plus transfection reagent using the manu The term "comprising encompasses “including as well facturer's protocol. Briefly, 1 lug of each plasmid (PA, PB1, as "consisting” e.g. a composition "comprising X may con PB2, NP, NS, M, HA, NA plus TMPRSS2) was diluted in 500 sist exclusively of X or may include something additional e.g. ul of serum-free DMEM medium. 10 ul of Plus reagent was X-Y. added directly to the diluted DNA. The mixture was incu The word “substantially” does not exclude “completely bated at room temperature Jim 5 minutes after which 25ul of e.g. a composition which is “substantially free” from Y may Lipofectamine was added to it. The mixture was then incu be completely free from Y. Where necessary, the word “sub bated at room temperature for 30 minutes. Following the stantially” may be omitted from the definition of the inven incubation, the transfection reagent:DNA complex was tion. 25 added to the cells in a drop-wise manner. The cells were The term “about in relation to a numerical value x is subsequently incubated at 37° C. for 24 hours. optional and means, for example, Xit 10%. Following the incubation, the medium was aspirated from Unless specifically stated, a process comprising a step of the cells and a suspension of 4x10 MDCK33016 cells in mixing two or more components does not require any specific serum-free DMEM medium containing a 1:2000 dilution of order of mixing. Thus components can be mixed in any order. 30 TrypzeanTM (1 mg/mL stock solution) was added to each Where there are three components then two components can well. In a parallel experiment, a 1:2000 dilution of be combined with each other, and then the combination may TrypzeanTM (1 mg/mL stock solution) alone, i.e. without be combined with the third component, etc. addition of cells, was added to the transfected cells. The cells Where animal (and particularly bovine) materials are used were then incubated at 37°C. for another 48 hours or until the in the culture of cells, they should be obtained from sources 35 cells were lysed after which the virus titre was determined that are free from transmissible spongiform encephalopathies using a Focus-Forming Assay. (TSEs), and in particular free from bovine spongiform Focus-Forming Assays encephalopathy (BSE). Overall, it is preferred to culture cells Uninfected MDCK cells were plated at a density of 6.25x in the total absence of animal-derived materials. 10 cells/well in 48 well plates in 500 ul of DMEM with 10% Where a compound is administered to the body as part of a 40 FCS. The next day cells were infected with viruses in a composition then that compound may alternatively be volume of 100-150 ul for 2 hours at 37° C. The cells were replaced by a Suitable prodrug. infected with various dilutions of the virus. Two hours post infection, the medium was aspirated and 500 ul of DMEM BRIEF DESCRIPTION OF THE DRAWINGS with 10% FCS was added to each well. The cells were incu 45 bated at 37°C. until the next day. FIG. 1: Schematic representation of an embodiment of the 24 hours after infection, the medium was aspirated and the present invention; MDCK33016 suspension cells (cultured cells washed once with PBS. 500 ul of ice-cold 80% acetone in CDM) are seeded in a 6-well dish A (in serum-free medium in PBS was added to each well followed by incubation at 4°C. or DMEM+5% PBS); B: co-transfection MDCK33016; C: for 30 minutes. The acetone mix was aspirated and the cells wash 2x, change to serum-free DMEM, +trypzean, +/-fresh, 50 washed once with PBST (PBS+0.1% Tween). 500 ul of 2% uninfected MDCK cells, D: RG virus BSA in PBS was added to each well followed by incubation FIG. 2: Efficiency of influenza virus rescue in MDCK at room temperature (RT) for 30 minutes. 500 ul of a 1:6000 33016 cells using the PR8-A/CAbackbone; the y-axis shows dilution of anti-NP was added in blocking buffer followed by infectious titre (FFU/mL); the open boxes show results with incubation at RT for 2 hours. The antibody solution was PR8-A/CA and 5% serum and the hatched boxes show results 55 aspirated and the cells washed twice with PBST. Secondary with PR8-A/CA and no serum; A indicates that fresh unin antibody (goat anti mouse) was added at a dilution 1:2000 in fected cells were added; B indicates that no fresh uninfected 500 ul blocking buffer and the plate was incubated at RT for cells were added. 2 hours. The antibody solution was aspirated and the cells FIG. 3: Efficiency of influenza virus rescue in MDCK washed three times with PBST.500 ul of KPL True Blue was 33016 cells using the A/WSN/33 backbone; the y-axis shows 60 added to each well and incubated for 10 minutes. The reaction infectious titre (FFU/mL); the open boxes show results with was stopped by aspirating the True-Blue and washing once WSN and 5% serum and the hatched boxes show results with with dHO. The water was aspirated and the cells left to dry. WSN and no serum; A indicates that fresh uninfected cells Results were added; B indicates that no fresh uninfected cells were The results of the focus forming assay with three different added. 65 viral backbones is shown in FIGS. 2-4. The results show the FIG. 4: Efficiency of influenza virus rescue in MDCK efficiency of the viral rescue with and without the addition of 33016 cells using the PR8-WSN backbone, the y-axis shows cells 24 hours after infection. As can be seen, in all cases the US 8,883,481 B2 23 24 efficiency of the viral rescue increased by up to three-fold in 24 WO02/074336. the experiments where cells were added 24 hours after trans 25 WO01/21151. fection compared to the experiments where no cells were 26 WO02/097072. added. This increase in efficiency can be seen with all tested 27 WO2005/113756. viral backbones and under both serum-containing and serum 28 Vaccines. (eds. Plotkins & Orenstein). 4th edition, 2004, free conditions. ISBN: 0-7216-9688-0 It will be understood that the invention has been described 29 Huckriede et al. (2003) Methods Enzymol 373:74–91. by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention. 30 Treanor et al. (1996).J Infect Dis 173:1467-70. 10 31 Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10. DEPOSIT INFORMATION 32 Herlocher et al. (2004).J Infect Dis 190(9): 1627-30. 33 Leet al. (2005) Nature 437(7062): 1108. A deposit of the microorganism MDCK 33016 (DSM 34 WO2008/068631. ACC2219) was deposited on Jun. 7, 1995 according to the 35 Gennaro (2000) Remington. The Science and Practice of Budapest Treaty in the International Depository Authority 15 Pharmacy. 20th edition, ISBN: 06833.06472. DSM-Deutsche Sammlung Von Mikroorganismen and 36 Banzhaf (2000) Immunology Letters 71:91-96. Zelkulturen GmbH, Mascheroder Weg 1b, D-38124 Braun 37. Nony et al. (2001) Vaccine 27:3645-51. Schweig. 38 EP-B-0870508. 39 U.S. Pat. No. 5,948,410. REFERENCES |40 WO2007/052163. 41 WO2007/052061 1 Racaniello and Baltimore (1981) Science 214:916-919 42 WO90/14837. 2 Kaplanet al. (1985) Proc Natl Acad Sci USA 82: 8424 43 Podda & Del Giudice (2003) Expert Rev. Vaccines 2:197 8428 2O3. 3 Fodor et al. (1999).J. Virol 73(11):9679-9682 25 44 Podda (2001). Vaccine 19: 2673-2680. 4 Hoffmann et al. (2002) Proc Natl Acad Sci USA 99: 45 Vaccine Design. The Subunit and Adjuvant Approach 1141 1-11416 (eds. Powell R. Newman) Plenum Press 1995 (ISBN 5. Kobayashi et al. (2007) Cell Host Microbe 19; 1(2): 147 0-306-44867-X). 57 46 Vaccine Adjuvants. Preparation Methods and Research 6 WO2009/000891 30 Protocols (Volume 42 of Methods in Molecular Medicine 7 Sambrook et al. Molecular Cloning: A Laboratory series). ISBN: 1-59259-083-7. Ed. O'Hagan. Manual, 2 ed., 1989, Cold Spring Harbor Press, Cold 47 WO2008/043774. Spring Harbor, N.Y 48 Allison & Byars (1992) Res Immunol 143:519-25. 8 Kistner et al. (1998) Vaccine 16:960-8, 49 Hariharan et al. (1995) Cancer Res 55:3486-9. 9 Kistner et al. (1999) Dev Biol Stand 98: 101-110, 35 50 US-2007/014805. 10 Bruhl et al. (2000). Vaccine 19:1149-58. 51 US-2007/0191314. 11 Pau et al. (2001). Vaccine 19:2716-21, 52 Suliet al. (2004) Vaccine 22(25-26):3464-9. 12 www.atcc.org/ 53 WO95/11700. 13 locus.umdnj.edui 54 U.S. Pat. No. 6,080,725. 14 WO97/37000. 40 55 WO2005/097181. 15 Brands et al. (1999) Dev Biol Stand 98:93-100. 56 WO2006/113373. 16 Halperinet al. (2002) Vaccine 20:1240-7. 57 Potter & Oxford (1979) Br Med Bull 35: 69-75. 17 EP-A-1260581 (WO01/64846) 58 Greenbaum et al. (2004) Vaccine 22:2566-77. 18 WO2006/071563 59 Zurbriggen et al. (2003) Expert Rev. Vaccines 2:295-304. |19 WO2005/113758 45 60 Piascik (2003) J Am Pharm Assoc (Washington D.C.). 20 WO97/37001 43:728-30. 21 Neumann et al. (2005) Proc Natl Acad Sci USA 102: 61. Mann et al. (2004) Vaccine 22:2425-9. 16825-9 62 Halperinet al. (1979) Am J Public Health 69:1247-50. 22 WO02/28422. 63. Herbert et al. (1979).J Infect Dis 140:234-8. 23 WO02/067983. 64 Chen et al. (2003) Vaccine 21:2830-6.
SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 4
<21 Oc SEO ID NO 1 <211 LENGTH: 566 <212> TYPE PRT <213> ORGANISM: Influenza A virus
<4 OOs SEQUENCE: 1 Met Lys Ala Ile Lieu Val Val Lieu. Lieu. Tyr Thr Phe Ala Thr Ala Asn 1. 5 1O 15 Ala Asp Thr Lieu. Cys Ile Gly Tyr His Ala Asn. Asn. Ser Thr Asp Thr 3 O US 8,883,481 B2 26 - Continued
Wall Asp Thir Wall Lell Glu Asn Wall Thir Wall Thir His Ser Wall Asn 35 4 O 45
Lell Luell Glu Asp Lys His Gly Luell Cys Lys Lell Arg Gly Wall SO 6 O
Ala Pro Luell His Lell Gly Asn Ile Ala Gly Trp Ile Luell Gly 65 70
Asn Pro Glu Glu Ser Lell Ser Thir Ala Ser Ser Trp Ser Tyr Ile 85 90 95
Wall Glu Thir Pro Ser Ser Asp Asn Gly Thir Pro Gly Asp Phe 105 11 O
Ile Asp Tyr Glu Glu Lell Arg Glu Glin Luell Ser Ser Wall Ser Ser Phe 115 12 O 125
Glu Arg Phe Glu Ile Phe Pro Thir Ser Ser Trp Pro Asn His Asp 13 O 135 14 O
Ser Asn Gly Wall Thir Ala Ala Pro His Ala Gly Ala Ser 145 150 155 160
Phe Asn Lell Ile Trp Luell Wall Lys Gly Asn Ser Tyr Pro 1.65 17O 17s
Luell Ser Lys Ser Ile Asn Asp Gly Glu Wall Luell Wall 18O 185 19 O
Lell Trp Gly Ile His His Pro Ser Thir Ser Ala Asp Glin Glin Ser Luell 195
Glin Asn Ala Asp Thir Tyr Wall Phe Wall Gly Ser Ser Arg Ser 21 O 215 22O
Lys Phe Pro Glu Ile Ala Ile Arg Pro Wall Arg Asp 225 23 O 235 24 O
Glu Gly Arg Met Asn Trp Thir Luell Wall Glu Pro Gly Asp 245 250 255
Ile Thir Phe Glu Ala Thir Gly Asn Luell Wall Wall Pro Arg Tyr Ala Phe 26 O 265 27 O
Ala Met Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp Thir Pro 28O 285
Wall His Asp Asn Thir Thir Glin Thir Pro Lys Gly Ala Ile Asn 29 O 295 3 OO
Thir Ser Luell Pro Phe Glin Asn Ile His Pro Ile Thir Ile Gly Cys 3. OS 310 315
Pro Wall Lys Ser Thir Luell Arg Luell Ala Thir Gly Luell Arg 3.25 330 335
Asn Ile Pro Ser Ile Glin Ser Arg Gly Luell Phe Gly Ala Ile Ala Gly 34 O 345 35. O
Phe Ile Glu Gly Gly Trp Thir Gly Met Wall Asp Gly Trp Gly 355 360 365
His His Glin Asn Glu Glin Gly Ser Gly Ala Ala Asp Luell Ser 37 O 375 38O
Thir Glin Asn Ala Ile Asp Glu Ile Thir Asn Lys Wall Asn Ser Wall Ile 385 390 395 4 OO
Glu Met Asn Thir Glin Phe Thir Ala Wall Gly Glu Phe Asn His 4 OS 415
Lell Glu Arg Ile Glu Asn Luell Asn Wall Asp Asp Gly Phe 425 43 O
Lell Asp Ile Trp Thir Asn Ala Glu Luell Luell Wall Lell Luell Glu Asn 435 44 O 445
Glu Arg Thir Luell Asp His Asp Ser Asn Wall Asn Luell Glu US 8,883,481 B2 27 28 - Continued
450 45.5 460 Llys Val Arg Ser Glin Lieu Lys Asn. Asn Ala Lys Glu Ile Gly Asn Gly 465 470 47s 48O Cys Phe Glu Phe Tyr His Lys Cys Asp Asn Thr Cys Met Glu Ser Val 485 490 495 Lys Asn Gly. Thir Tyr Asp Tyr Pro Llys Tyr Ser Glu Glu Ala Lys Lieu. SOO 505 51O Asn Arg Glu Glu Ile Asp Gly Val Lys Lieu. Glu Ser Thr Arg Ile Tyr 515 52O 525 Glin Ile Lieu Ala Ile Tyr Ser Thr Val Ala Ser Ser Lieu Val Lieu Val 53 O 535 54 O Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 5.45 550 555 560 Glin Cys Arg Ile Cys Ile 565
<210s, SEQ ID NO 2 &211s LENGTH: 566 212. TYPE: PRT <213> ORGANISM: Influenza A virus
<4 OOs, SEQUENCE: 2 Met Lys Ala Lys Lieu. Lieu Val Lieu. Lieu. Cys Ala Lieu. Ser Ala Thr Asp 1. 5 1O 15 Ala Asp Thir Ile Cys Ile Gly Tyr His Ala Asn. Asn. Ser Thr Asp Thr 2O 25 3O Val Asp Thr Val Lieu. Glu Lys Asn Val Thr Val Thr His Ser Val Asn 35 4 O 45 Lieu. Lieu. Glu Asp Asn His Asn Gly Lys Lieu. Cys Llys Lieu Lys Gly Ile SO 55 6 O Ala Pro Lieu. Glin Lieu. Gly Lys Cys Ser Ile Ala Gly Trp Ile Lieu. Gly 65 70 7s 8O Asn Pro Glu. Cys Glu Ser Leu Phe Ser Lys Llys Ser Trp Ser Tyr Ile 85 90 95 Ala Glu Thr Pro Asn Ser Glu Asn Gly Thr Cys Tyr Pro Gly Tyr Phe 1OO 105 11 O Ala Asp Tyr Glu Glu Lieu. Arg Glu Gln Lieu. Ser Ser Val Ser Ser Phe 115 12 O 125 Glu Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Llys His Asn 13 O 135 14 O Val Thir Lys Gly Val Thr Ala Ala Cys Ser His Lys Gly Lys Ser Ser 145 150 155 160 Phe Tyr Arg Asn Lieu Lleu Trp Lieu. Thr Glu Lys Asn Gly Ser Tyr Pro 1.65 17O 17s Asn Lieu. Ser Lys Ser Tyr Val Asn. Asn Lys Glu Lys Glu Val Lieu Val 18O 185 19 O Lieu. Trp Gly Val His His Pro Ser Asn Ile Glu Asp Gln Lys Thir Ile 195 2OO 2O5 Tyr Arg Lys Glu Asn Ala Tyr Val Ser Val Val Ser Ser His Tyr Asn 21 O 215 22O
Arg Arg Phe Thr Pro Glu Ile Ala Lys Arg Pro Llys Val Arg Asn Glin 225 23 O 235 24 O
Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Lieu. Leu Glu Pro Gly Asp Thr 245 250 255 US 8,883,481 B2 29 30 - Continued
Ile Ile Phe Glu Ala Asn Gly Asn Luell Ile Ala Pro Trp Tyr Ala Phe 26 O 265 27 O
Ala Luell Ser Arg Gly Phe Gly Ser Gly Ile Ile Thir Ser Asn Ala Ser 27s 28O 285
Met Asp Glu Ala Lys Glin Thir Pro Glin Gly Ala Ile Asn 29 O 295 3 OO
Ser Ser Luell Pro Phe Glin Asn Wall His Pro Wall Thir Ile Gly Glu Cys 3. OS 310 315
Pro Val Arg Ser Thir Luell Arg Met Wall Thir Gly Luell Arg 3.25 330 335
Asn Ile Pro Ser Ile Glin Ser Arg Gly Luell Phe Gly Ala Ile Ala Gly 34 O 345 35. O
Phe Ile Glu Gly Gly Trp Thir Gly Met Ile Asp Gly Trp Gly 355 360 365
His His Glin Asn. Glu Glin Gly Ser Gly Ala Ala Asp Glin Ser 37 O 375
Thir Glin Asn Ala Ile Asn Gly Ile Thir Asn Lys Wall Asn Ser Ile Ile 385 390 395 4 OO
Glu Met Asn. Thir Glin Phe Thir Ala Wall Gly Glu Phe Asn 4 OS 41O 415
Lell Glu Arg Met Glu Asn Luell Asn Wall Asp Asp Gly Phe 42O 425 43 O
Lell Asp Ile Trp Thr Asn Ala Glu Luell Luell Wall Lell Luell Glu Asn 435 44 O 445
Glu Arg Thr Lieu. A Sp Phe His Asp Ser Asn Wall Lys Asn Luell Glu 450 45.5 460
Lys Wall Ser Glin Lell Asn Asn Ala Lys Glu Ile Gly Asn Gly 465 470
Phe Glu Phe Tyr His Asn Asn Glu Met Glu Ser Wall 485 490 495
Asn Gly Thr Tyr Asp Pro Lys Ser Glu Glu Ser Luell SOO 505
Asn Arg Glu Lys Ile Asp Gly Wall Luell Glu Ser Met Gly Wall 515 52O 525
Glin Ile Luell Ala Ile Ser Thir Wall Ala Ser Ser Lell Wall Luell Luell 53 O 535 54 O
Wall Ser Luell Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Luell 5.45 550 555 560
Glin Arg Ile Cys Ile 565
<210s, SEQ ID NO 3 &211s LENGTH: 469 212. TYPE : PRT &213s ORGANISM: Influenza A virus
<4 OOs, SEQUENCE: 3
Met Asn. Pro Asn. Glin Ile Ile Thir Ile Gly Ser Wall Met Thir 1. 5 15
Ile Gly Met Ala Asn Lell Ile Luell Glin Ile Gly Asn Ile Ile Ser Ile 25 3O
Trp Ile Ser His Ser Ile Glin Luell Gly Asn Glin Asn Glin Ile Glu Thir 35 4 O 45
Cys Asn Glin Ser Val Ile Thir Glu Asn ASn Thir Trp Wall Asn Glin SO 55 6 O US 8,883,481 B2 31 32 - Continued
Thir Wall Asn Ile Ser Asn Thir Asn Phe Ala Ala Gly Glin Ser Wall 65 70
Wall Ser Wall Lys Lell Ala Gly Asn Ser Ser Luell Pro Wall Ser Gly 85 90 95
Trp Ala Ile Tyr Ser Asp Asn Ser Wall Arg Ile Gly Ser Gly 105 11 O
Asp Wall Phe Wall Ile Arg Glu Pro Phe Ile Ser Ser Pro Luell Glu 115 12 O 125
Arg Thir Phe Phe Lell Thir Glin Gly Ala Luell Lell Asn Asp His 13 O 135 14 O
Ser Asn Gly Thir Ile Lys Asp Arg Ser Pro Tyr Arg Thir Luell Met Ser 145 150 155 160
Pro Ile Gly Glu Wall Pro Ser Pro Tyr ASn Ser Arg Phe Glu Ser 1.65 17O 17s
Wall Ala Trp Ser Ala Ser Ala His Asp Gly Ile Asn Trp Luell Thir 18O 185 19 O
Ile Gly Ile Ser Gly Pro Asp Asn Gly Ala Wall Ala Wall Luell Tyr 195
Asn Gly Ile Ile Thir Asp Thir Ile Ser Trp Arg Asn Asn Ile Luell 21 O 215
Arg Thir Glin Glu Ser Glu Ala Wall ASn Gly Ser Phe Thir 225 23 O 235 24 O
Wall Met Thir Asp Gly Pro Ser Asn Gly Glin Ala Ser Ile Phe 245 250 255
Arg Ile Glu Lys Gly Ile Wall Lys Ser Wall Glu Met Asn Ala Pro 26 O 265 27 O
Asn Tyr His Glu Glu Ser Pro Asp Ser Ser Glu Ile 27s 28O 285
Thir Cys Wall Asp Asn Trp His Gly Ser Asn Arg Pro Trp Wall 29 O 295 3 OO
Ser Phe Asn Glin Asn Lell Glu Tyr Glin Ile Gly Tyr Ile Ser Gly 3. OS 310 315
Ile Phe Gly Asp Asn Pro Arg Pro Asn Asp Thir Gly Ser Cys Gly 3.25 330 335
Pro Wall Ser Ser Asn Gly Ala Asn Gly Wall Gly Phe Ser Phe 34 O 345 35. O
Gly Asn Gly Wall Trp Ile Gly Arg Thir Ser Ile Ser Ser Arg 355 360 365
Asn Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thir Gly Thir Asp 37 O 375
Asn Asn Phe Ser Ile Lys Glin Asp Ile Wall Gly Ile Asn Glu Trp Ser 385 390 395 4 OO
Gly Tyr Ser Gly Ser Phe Wall Glin His Pro Glu Lell Thir Gly Luell Asp 4 OS 41O 415
Ile Arg Pro Phe Trp Wall Glu Luell Ile Arg Gly Arg Pro 425 43 O
Glu Asn Thir Ile Trp Thir Ser Gly Ser Ser Ile Ser Phe Gly Wall 435 44 O 445
Asn Ser Asp Thir Wall Gly Trp Ser Trp Pro Asp Gly Ala Glu Luell Pro 450 45.5 460
Phe Thir Ile Asp 465 US 8,883,481 B2 33 34 - Continued
<210s, SEQ ID NO 4 &211s LENGTH: 470 212. TYPE : PRT &213s ORGANISM: Influenza A virus
<4 OOs, SEQUENCE: 4.
Met Asn. Pro Asn Glin Ile Ile Thir Ile Gly Ser Ile Met Thir 1. 15
Ile Gly Ile Ile Ser Lell Ile Luell Glin Ile Gly Asn Ile Ile Ser Ile 25 3O
Trp Wall Ser His Ser Ile Glin Thir Gly Ser Glin Asn His Thir Gly Ile 35 4 O 45
Asn Glin Arg Ile Ile Thir Glu Asn Ser Thir Trp Wall Asn Glin SO 55 6 O
Thir Wall Asn Ile Asn Asn Thir Asn Wall Wall Ala Gly Asp Thir 65 70
Thir Ser Wall Thir Lell Ala Gly Asn Ser Ser Luell Pro Ile Arg Gly 85 90 95
Trp Ala Ile Tyr Ser Asp Asn Ser Ile Arg Ile Gly Ser Gly 105 11 O
Asp Wall Phe Wall Ile Arg Glu Pro Phe Ile Ser Ser His Luell Glu 115 12 O 125
Arg Thir Phe Phe Lell Thir Glin Gly Ala Luell Lell Asn Asp His 13 O 135 14 O
Ser Asn Gly Thir Wall Lys Asp Arg Ser Pro Tyr Arg Ala Luell Met Ser 145 150 155 16 O
Pro Ile Gly Glu Ala Pro Ser Pro Tyr ASn Ser Arg Phe Glu Ser 1.65 17O 17s
Wall Ala Trp Ser Ala Ser Ala His Asp Gly Met Gly Trp Luell Thir 18O 185 19 O
Ile Gly Ile Ser Gly Pro Asp Asp Gly Ala Wall Ala Wall Luell Tyr 195
Asn Gly Ile Ile Thir Glu Thir Ile Ser Trp Arg Arg Ile Luell 21 O 215
Arg Thir Glin Glu Ser Glu Wall Wall ASn Gly Ser Phe Thir 225 23 O 235 24 O
Ile Met Thir Asp Gly Pro Ser Asn Gly Pro Ala Ser Arg Ile Phe 245 250 255
Ile Glu Lys Gly Ile Thir Lys Ser Ile Glu Lell Asp Ala Pro 26 O 265 27 O
Asn Ser His Glu Glu Ser Pro Asp Thir Gly Thir Wall 27s 28O 285
Met Cys Wall Asp Asn Trp His Gly Ser Asn Arg Pro Trp Wall 29 O 295 3 OO
Ser Phe Asn Glin Asn Lell Asp Glin Ile Gly Ile Ser Gly 3. OS 310 315 32O
Wall Phe Gly Asp Asn Pro Arg Pro Asp Gly Gly Ser Cys Asp 3.25 330 335
Pro Wall Thir Wall Asp Gly Ala Asp Gly Wall Gly Phe Ser 34 O 345 35. O
Gly Asn Gly Wall Trp Ile Gly Arg Thir Ser Asn Ser Ser Arg 355 360 365
Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thir Asp Thir Asp 37 O 375 38O US 8,883,481 B2 35 36 - Continued
Ser Asn Phe Luell Wall Lys Glin Asp Wal Wall Ala Met Thr Asp Trp Ser 385 390 395 4 OO
Gly Tyr Ser Gly Ser Phe Wall Glin His Pro Glu Lieu. Thir Gly Luell Asp 4 OS 415
Met Arg Pro Phe Trp Wall Glu Lieu Wall Arg Gly Arg Pro Arg 425 43 O
Glu Gly Thir Thir Wall Trp Thir Ser Gly Ser Ser Ile Ser Phe Gly 435 44 O 445
Wall Asn. Ser Asp Thir Ala Asn Trp Ser Trp Pro Asp Gly Ala Glu Lieu. 450 45.5 460
Pro Phe Thir Ile Asp Llys 465 470
The invention claimed is: 3. A method for preparing an influenza virus for vaccine 1. A method for preparing an influenza virus comprising manufacture, comprising steps (i)-(iii) of claim 2, and further the steps of (i) transfecting a culture of mammalian kidney comprising (iv) purifying the virus obtained in step (iii). cells with at least one expression construct encoding an influ enza RNA molecule; (ii) adding untransfected mammalian 4. The method of claim 1, wherein the mammalian kidney cell is a VERO or MDCK cell. kidney cells to the transfected cells of step (i) to provide a 25 mixture of cells, wherein the untransfected cells are of the 5. The method of claim 2, wherein the MDCK cell is the same type as the cells of step (i); and (iii) culturing the cell line MDCK33016 (DSMACC2219). mixture of cells from step (ii) in order to produce influenza W1US. 6. The method of claim 3, further comprising the step of 2. A method for preparing an influenza virus comprising formulating the virus purified in step (iv) into a vaccine. the steps of (i) transfecting a culture of MDCK cells with at 30 7. The method of claim 1, wherein the cells are cultured in least one expression construct encoding an influenza RNA Suspension. molecule; (ii) adding untransfected MDCK cells to the trans fected MDCK cells of step (i) to provide a mixture of MDCK 8. The method of claim 1, wherein the cells are cultured cells; and (iii) culturing the mixture of MDCK cells in order adherently. to produce influenza virus.